An Oral Plasmacytoid Mass: The Result of a Malcontrolled Multiple Myeloma

Narges Mirjalili,¹ Mohammah-Hassan Akhavan Karbassi,¹ Ali-Akbar Davoudi¹  
¹Department of Oral Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Corresponding author: Nargess Mirjalili, Assistant professor in oral medicine  
Fazay-e-sabz square, Department of oral medicine, Shahid Sadoughi university of medical sciences, Yazd, Iran  
Tel: +3516212222, +989124024930  
E-mail: nargess1981@yahoo.com  
Co-author one: Mohammad-Hassan Akhavan Karbassi, drkarbassi@gmail.com  
Co-author two: Ali-Akbar Davoudi, aadavoudiom@gmail.com

Abstract
Introduction: Multiple myeloma is a neoplasm of monoclonal plasma cells which may cause oral manifestations. We report a 50-year-old man with a mass burned out of a post extraction socket. He had received an eight month period of chemotherapy and was supposed to be ready for hematopoetic stem cell transplantation. After clinical and histopathological examinations, the mass was diagnosed as a plasmacytoid cell proliferation. As the oral manifestations are an indicator of poorly controlled disease, the patient was referred to change his chemotherapeutic regimen.

Conclusion: It seems that a team work, including oral medicine specialists may be a valuable opportunity in monitoring and promoting the quality of therapy.

Keywords: Multiple myeloma, Oral manifestations, Oral medicine

Introduction
Multiple myeloma represents a neoplastic growth of monoclonal plasma cells (1). The cancerous cells primarily involve the bone marrow spaces in multiple sites and then may involve extramedullary tissues. (2) Clinical manifestations of the disease such as pain, pathologic fractures, renal failure and recurrent infections are results of aberrant cell proliferation, neoplastic products and host responses. (2, 3) In head and neck region, radiolucent punched-out or ragged border bone lesions, soft tissue amyloid deposition and intra-oral metastatic tumoral masses may be seen especially as late consequences of disease. (4-7)

Management of patients with multiple myeloma is fundamentally directed toward regression of the malignant process and palliation of symptoms. (1, 8-9) In past 2 decades, Hematopoetic stem cell transplantation (HSCT) has been vastly used beside conventional or modified chemotherapeutic regimens.(9-13) HSCT is a way to prolong the event free survival of patients and is better to be done after the first successful induction therapy. (3, 14)

Emerging manifestations of multiple myeloma in oral cavity, is a strong indicator of uncontrolled disease progression. (4, 7)  

Case presentation
A 50-year-old man with multiple myeloma, attended to Oral medicine center of Yazd medical university for pre-transplant oral health evaluation. His disease was first diagnosed following a spontaneous fracture in his upper extermity. The patient had received a chemotherapeutic regimen of melphanal and dexamethasone for eight months and was assumed to be ready for HSCT. In first visit, the patient complained of a mass that appeared 3 weeks ago in his mouth, after a tooth extraction. He mentioned a history of a prolonged deep pain in his right angle of mandible. This situation convinced his oncologist to refer him for dental treatments. Then diagnosing a deep carious tooth in his lower left quadrant, rationalized its extraction.

Intra-oral examinations revealed a non-healing tooth socket and a 1×1.5 cm mass, burned out of the socket. It was rubbery in palpation and fixed to underlying bone. Panoramic radiography merely showed a non-healing post extraction socket. Our differential diagnosis was ordered as below:

1. Plasmacytoma/ Multiple myeloma  
2. Lymphoma  
3. Central giant cell granuloma  

Complete blood cell count, PT/INR and BT tests were requested in order to perform a surgical
diagnostic incisional biopsy. Although the laboratory values were all within normal limits and the patient was supposed to be in remission phase, we encountered a bleeding situation. Despite the restricted surgical field, the volume of bleeding was enormous and hardly controlled by local hemostatic modalities. The excised tissue was very fragile and suturing of surgical margins was too difficult.

Histopathological study of the obtained specimen indicated diffuse monotonous sheets of variably differentiated malignant plasmacytoid cells which was compatible with plasmacytoma. Further radiographic examinations revealed multiple punched-out lytic lesions of the skull. All the evidences confirmed our first diagnosis and implied the malignant process did not respond to provided chemotherapeutic regimen.

We referred the patient to his oncologist, recommending to switch the chemotherapy plan. HSCT was carried out after the first remission, about one year past our first visit. The patient is alive by the time of this paper and the oral cavity is disease free.

Discussion

Multiple myeloma primarily involves the bone in a multi-centric fashion but is considered a hematologic cancer of monoclonal plasma cell origin.\(^1\) It arises from bone marrow spaces and rarely manifests as soft tissue metastases.\(^2, 15\) Neoplastic cells can replace the normal hematopoetic cell lines, destruct involved bones and waste the body resources by producing aberrant proteins. Accordingly, skeletal pain, pathologic fractures, hypercalcemia, anemia, frequent infections, bleeding tendency and renal impairment are not unexpected in the course of the disease.\(^1, 16\)

In head and neck region, the most common features are osteolytic lesions of skull, cervical spine and posterior mandibular areas which may lead to pain, paresthesia, tooth loosening and fracture.\(^6, 4, 7, 15\) Patients with multiple myeloma, also may manifest plasmabelastic soft tissue masses in oral cavity.\(^17-19\)

In the present case, we encountered a chief complaint of a mass, burned out of a post-extraction socket. It was rubbery in consistency and fixed to underlying tissue. There was also a history of a continuous deep pain in that area of posterior mandible. A list of differential diagnosis was arranged based on the clinical findings and medical history. At the lowest rank, one may consider a giant cell lesion as the probable diagnosis. Renal dysfunction secondary to multiple myeloma, cytokine profile of the disease and abnormal osteoclastic activity, may all disturb the normal bone turnover.\(^1-3\) So it is not impossible if a central giant cell lesion forms. Central giant cell lesions prefer to emerge through less resistant parts of jaw bone into the oral cavity and may bleed heavily during surgical interventions.\(^20\)
On the other hand, these pathoses usually are firm in palpation, frequently involve anterior mandible, expand the involved bone, and are very rare in this context.(20) As the underlying disease would be recognized much more earlier, it seems impossible to progress to such a condition. The second possible diagnosis could be chemotherapy induced Lymphoma. Cytotoxic drugs usually have low therapeutic indexes. They affect both normal and neoplastic cells. Long term consumers of chemotherapeutic agents are at a greater risk for developing secondary hematologic cancers than normal population.(21)

Involving lower jaw especially in the posterior parts, burning out of an extraction socket, rubbery consistency, fragility and bleeding tendency are all characteristics of extra-nodular lymphomas.(6, 20)

This assumption is potentiated when highlighting an eight month use of melphalan in patient’s history.

Considering the background medical status of the patient, it was reasonable to put the extra-medullary plasmacytoid mass in the top rank of our differential diagnosis. The history and the clinical, surgical and histopathological findings were all consistent with the diagnosis of multiple myeloma. Multiple myeloma is a rare malignancy with a wide range of complications.

It is very unexpected to see mouth lesions as the first manifestation of the disease and oral involvements such as pain, paresthesia of inferior alveolar nerve, tooth loss, osteolytic lesions of jaw, amyloidosis, gingival masses and peripheral plasmacytoid tumors are more prone in progressive or uncontrolled disease.

During the treatment course, high-dose chemotherapeutic drugs may affect both directly and indirectly the mouth, and for a successful HSCT, stabilishing optimal oral hygiene, removing infectious sources and providing a healthy oral environment is a critical consideration. So the spectacular role of an oral medicine specialist is underlined in all stages of the disease from diagnosis to monitoring chemotherapeutic regimens efficacy and/or preparing for HSCT.

**Conclusion**

Considering the available evidences, we suggest that the oral medicine specialists become involved in close monitoring of medical management of patients with multiple myeloma and it would be appreciated if medical care providers use the advantage of our consultations in this regard.

**References**
